Objective The management of diabetes mellitus includes controlling the blood glucose level, body weight, blood pressure and serum lipid level. The coexistence of diabetes and a high low-density lipoprotein cholesterol (LDL-C) level promotes atherosclerosis of the coronary arteries and increases the risk of coronary artery disease (CAD). We compared the rates of attainment of LDL-C goals in type 2 diabetes patients receiving primary and secondary prevention therapy, the former without a history of CAD and the latter with a history of CAD. Because patients receiving secondary prevention are at greater risk of coronary events, LDL-C management is especially important in this group. This study was designed to determine how frequently diabetic patients attain their LDL-C goals and identify the reasons for the lack of attainment. Methods The groups were distinguished according to the patients' medical records. Contributory factors for the patients not achieving their goals were recorded in a questionnaire filled out by each patient's physician. Results The overall attainment rate in both groups was 61%. The most frequent impediment in both groups was "an LDL-C level above or below the goal at every hospital visit" followed by "continuously sufficient effects of dietary therapy only" and the "management of LDL-C by other departments or hospitals," the latter reflecting the increasing problems of polydisease and polypharmacy in diabetes care. Conclusion Polydisease and polypharmacy issues in diabetes patients with a history of CAD constitute a growing barrier to medication adherence and the attainment of treatment goals.
Introduction
The coexistence of diabetes and a high low-density lipoprotein cholesterol (LDL-C) level promotes atherosclerosis of the coronary arteries and increases the risk of coronary artery disease (CAD) and its associated morbidity. Treatment for high LDL-C includes dietary intervention, exercise and pharmacological therapy. Representative LDL-C-lowering GI  11  3  11  1  TZD  1  0  1  0  SU+ -GI  11  9  4  2  SU+BG  33  5  4  1  SU+TZD  2  1  0  0  GLN+BG  4  0  0  0  -GI+TZD  1  0  0  0  BG+TZD  1  0  0  1  GLN+ -GI  0  0  1  1  -GI+BG  0  0  3  0  GLN+TZD  0  1  0  0  SU+ -GI+BG  16  3  2  0  SU+ -GI+TZD  3  1  0  0  SU+BG+TZD  1  2  0  0  -GI+BG+TZD  1  0  0  0  SU+ -GI+TZD+BG  3  0  0  0 In the present study, diabetes patients with no prior history of CAD comprised the primary prevention group, while those with a history of CAD comprised the secondary prevention group, the latter of which is more likely to develop new coronary events. According to the guidelines for the prevention of atherosclerosis-associated disease issued by the Japan Atherosclerosis Society in 2007, an LDL-C level less than 120 mg/dL is the goal for diabetes patients treated with primary prevention and an LDL-C level less than 100 mg/dL is the goal for patients treated with secondary prevention (9) . In addition, recent randomized trials have demonstrated that intensive statin therapy lowers the LDL-C level more effectively than standard statin therapy (10, 11) .
Diabetes patients often have hypertension as well as a high LDL-C level, which can be effectively treated with oral hypoglycemic, antihypertensive and lipid-lowering medications. For secondary prevention, antiplatelet agents and vasodilator agents are additionally added. In such cases, the medication to treat each disease is frequently prescribed separately by different physicians. Such complex polydisease and polypharmacy issues are a growing barrier to medication adherence and the attainment of treatment goals in the US (12) .
In Japan, no investigations have addressed the reasons for the lack of attainment of LDL-C goals.
In the present study, we surveyed the attainment rates for LDL-C goals in diabetes patients receiving primary and secondary prevention. In addition, a physician's questionnaire regarding the patients' lack of achievement of the goals was distributed and analyzed. The most frequent response regarding the lack of achievement in secondary prevention was the "management of LDL-C by other departments or hospitals," which reflects the increasing polydisease and polypharmacy issues in current diabetes care. 
Materials and Methods

Subjects
All patients regularly visited the outpatient clinic of Kyoto University Hospital and received nutritional instruction by dietitians. Because a total cholesterol (TC) level of 200 mg/dL corresponds to an LDL-C level of 120 mg/ dL (13), patients with a TC level higher than 200 mg/dL or those previously treated with statins were enrolled in December 2007 (Table 1A , B). The LDL-C level was measured at least once between January and July 2008. Subjects with familial hypercholesterolemia or secondary hypercholesterolemia, such as those with nephrotic syndrome or hypothyroidism, were excluded. Data for the period January 1 to July 31 2008 were prioritized nearest to March 15, 2008 .
Methods
The primary and secondary prevention groups were determined according to the patients' medical records. Standard statin therapy included pravastatin, simvastatin or fluvastatin, and intensive statin therapy included atorvastatin, pitavastatin or rosuvastatin. The maximum dose of each statin based on the medical package insert was as follows: pravastatin: 20 mg, simvastatin: 20 mg, fluvastatin: 60 mg, atorvastatin: 20 mg, pitavastatin: 4 mg and rosuvastatin: 10 mg. For several enrolled patients, the following lipid-lowering drugs were additionally prescribed: ethyl icosapentate, probucol, colestimide, fibrate and nicotinate. The LDL-C level was measured according to the selective solubilization method (Determiner L LDL-C test kit, Kyowa Medex Co., Ltd., Tokyo, Japan). The HbA1c level was measured using HPLC (HA-8180; Arcray, Kyoto, Japan). The HbA1c value (%) was estimated as the National Glycohemoglobin Standardization Program equivalent (%) according to the following formula: HbA1c (%) = HbA1c (JDS) (%) + 0.4%, considering the relational expression of HbA1c (JDS) (%) measured according to the previous Japanese standard substance and measurement methods and HbA1c (National Glycohemoglobin Standardization Program) (14) .
Questionnaire analysis
The questionnaire consisted of 14 items, as shown in Table 2. The factors contributing to why the patients did not achieve their goals were recorded in the questionnaire by each patient's physician.
Statistical analysis
The data are presented as the mean ± SE. The Chi-square test or Fisher's exact probability test were used to the evaluate results. p values of <0.05 were considered to be statistically significant. Table 1A shows the demographic characteristics of the enrolled patients. The primary prevention group comprised 499 patients (men: 219 and women: 280) 65.8±0.5 years of age, with a body mass index (BMI) of 24.1±0.2 kg/m 2 and a systolic and diastolic blood pressure of 127.5±0.7 mmHg and 73.9±0.4 mmHg, respectively. The HbA1c, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglyceride levels were 7.7±0.1%, 112.7±1.0 mg/dL, 55.0±0.6 mg/ dL and 154.0±5.0 mg/dL, respectively. Regarding treatment for hyperglycemia, 92, 222, 129 and 56 patients were treated with diet alone, OHAs (oral hypoglycemic agents), insulin and insulin plus OHAs, respectively. Table 1B shows the number of patients treated with SUs (sulfonylureas), GLNs (rapid-acting insulin secretagogues), BGs (biguanides), α-GIs (α-glucosidase inhibitors), TZD (thiazolidinedione) and a combination of these drugs in the presence and absence of insulin treatment. The frequency of SU+α-GI therapy in the secondary prevention group was significantly higher than that observed in the primary prevention group (p<0.01). The frequency of other OHAs in the secondary prevention group was indistinguishable from that observed in the primary prevention group. Table 3A summarizes the rates of attainment for the LDL-C goals. In the primary prevention group, 300 subjects achieved the LDL-C goal, an achievement of 61%. The patients received standard statin therapy (n=116), intensive statin therapy (n=144) or no statin therapy (n=239). The attainment rates in the patients treated with standard statin therapy, intensive statin therapy and no statin therapy were 73%, 80% and 42%, respectively. We further analyzed the following four subgroups: (1) the maximum dose of standard statins, (2) the non-maximum dose of standard statins, (3) the maximum dose of intensive statins and (4) the nonmaximum dose of intensive statins.
Results
Characteristics of the enrolled patients
Attainment rates for the LDL-C goals
In the secondary prevention group, 74 patients achieved the LDL-C goal, an achievement rate of 61% (Table 3A) . These patients also received standard statin therapy (n=10), intensive statin therapy (n=18) or no statin therapy (n=19) with attainment rates of 58%, 74% and 30%, respectively. We further analyzed the above-described four subgroups in the secondary prevention group. Table 3B shows the number of patients treated with other lipid-lowering drugs besides statins (ethyl icosapentate, probucol, colestimide, fibrate and nicotinate). Of those receiving combination therapy with a statin and other lipidlowering drugs, 0% received the maximum dose of the statin. Table 3C shows the rate of attainment of the LDL-C goal in the patients receiving additional lipid-lowering drugs. In the primary prevention group, the patients treated with combination therapy with a statin and other lipidlowering drugs showed only a statistically insignificant higher goal attainment rate than those treated with single statin therapy (standard statins: 73% vs. 77%; intensive statins: 79% vs. 100%). Table 4A summarizes the details of the statin administration. In the primary prevention group, of the patients attaining the LDL-C goal, 28% received standard statin therapy, 39% received intensive statin therapy and 33% received no statin therapy. Of those not attaining the goal, 16% received standard statin therapy, 14% received intensive statin therapy and 70% received no statin therapy. In the secondary prevention group, of the patients attaining the LDL-C goal, 19% received standard statin therapy, 70% received intensive statin therapy and 11% received no statin therapy. Of those not attaining the goal, 22% received standard statin therapy, 38% received intensive statin therapy and 40% received no statin therapy. Table 4B summarizes the details of the statin administration associated with additional lipid-lowering drugs in the patients attaining and not attaining the LDL-C goal.
Effectiveness of statin therapy
Questionnaire analysis
The background characteristics of the patients who did not achieve their goal were analyzed using a questionnaire completed by each patient's physician. Table 2 shows the questionnaires for the primary and secondary prevention groups.
In the primary prevention group, the three most frequent reasons for the lack of goal attainment were: (1) an LDL-C level above or below the goal at every hospital visit (47%), (2) continuously sufficient effects with dietary therapy only (34%) and (3) low compliance (6%). In the secondary prevention group, the reasons for the lack of goal attainment were: (1) an LDL-C level above or below the goal at every hospital visit (49%), (2) management of the LDL-C level by other departments or hospitals (45%) and (3) continuously sufficient effects with dietary therapy only (11%).
Discussion
In the present study, 61% of the patients in both the primary and secondary prevention groups achieved the LDL-C goal. A study in a university hospital setting in 2001 reported rates of achievement of 56% and 33% in primary and secondary prevention groups, respectively, with a considerably lower rate in the secondary prevention group (15) . In the present study, more intensive therapy was associated with an increased LDL-C goal attainment rate; the earlier study did not include intensive statin therapy. Recent randomized controlled trials have demonstrated that intensive statin therapy more effectively lowers the LDL-C level than standard statin therapy (10, 11) . In our follow-up study conducted in 2010, the attainment rates for the LDL-C goal reached 71% and 67% in the primary and secondary prevention groups, respectively (unpublished data).
Unexpectedly, 38% of the secondary prevention patients not attaining the LDL-C goal were treated with intensive statin therapy, which indicates a limitation of this treatment. Similarly, 43% of the secondary prevention patients treated with another lipid-lowering drug who did not attain the LDL-C goal also received intensive statin therapy. In fact, in one recent study, cholesterol absorption was reported to be elevated in the secondary prevention group (16), suggesting statin resistance.
Therefore, a high LDL-C level accompanied by statin resistance may be better treated with a combination of statins and cholesterol transporter inhibitors. Very recently, such combination therapy was found to be more effective than statin monotherapy in secondary prevention patients (17) . Ezetimibe use was not considered in this study; therefore, further investigation is required. This is the first study to analyze the background of diabetes patients in Japan who do not attain their LDL-C goal. This is also the first study to use a physician questionnaire to analyze the lack of achievement of LDL-C goals in indi- vidual patients. Recently, a physician questionnaire regarding barriers to lipid goal attainment in patients with type 2 diabetes was used in a web-based international survey (18) . That study found patient compliance to be the most common impediment, followed by financial restrictions to access to the product, lack of efficacy of available drugs and drug intolerability. Another group reported that the limited amount of time available during clinic visits is a barrier to the ideal management of the LDL-C level in diabetic patients (19) . In the present study, statin intolerance and adverse effects were observed in several patients, consistent with previous results. Our questionnaire regarding the lack of achievement of individual patients reflects the details of medical treatment not evaluated using other methods.
In the present study, we found the most frequent reason for the lack of goal attainment in both groups to be a "LDL-C level above or below the goal at every hospital visit." The data for the period January 1 to July 31 2008 were prioritized nearest to March 15, 2008 . In several patients, the LDL-C level nearest to March 15 happened to be above the goal, while the levels observed in other months were below the goal. Such occasional fluctuation underlies the "lack of goal attainment of the LDL-C level." This suggests that a certain number of patients may have attained an LDL-C level on the borderline of the goal, indicating that more potent drug therapy may be required.
In the secondary prevention group, the "management of the LDL-C level by other departments or hospitals" was reported with a high frequency. In several patients, particularly those in the secondary prevention group, other departments or hospitals often managed the dyslipidemia therapy and prescribed statins; however, the goal was not attained. In general, the secondary prevention group exhibited several chronic diabetic complications, such as coronary artery disease, retinopathy, nephropathy and neuropathy. In such cases, the medications for each complication may be separately prescribed. Therefore, polydisease might well result in poorer medication adherence. Although the health care system in Japan differs considerably from that observed in the US and elsewhere, polydisease and polypharmacy issues in diabetes care may well become a growing barrier to medication adherence and the attainment of treatment goals. Because patients treated with secondary prevention are more likely to develop new coronary events than those treated with primary prevention, controlling the LDL-C level is especially important in secondary prevention patients. To improve medication adherence, providing team medical care, including the participation of pharmacists and physicians in other fields, is essential.
Several limitations of this study should be considered.
First, the TC level rather than the LDL-C level was used for screening because direct measurement of the LDL-C level was not performed in several patients. Calculating the LDL-C level using Friedewald's equation with the TC, HDL-C and fasting TG levels is another method of determining the LDL-C level. For a considerable number of patients, however, the appointment time in the outpatient department was in the afternoon, when it is difficult to measure the fasting TG level, in which case, Friedewald's equation cannot be used. Strictly speaking, patients administered no statin therapy who attain the LDL-C goal but have a TC level over 200 mg/dL are expected to have a normal LDL-C level.
Very few patients with a TC level under 200 mg/dL are expected to have an LDL-C level over 120 mg/dL and not be included. Second, this study was performed in a single university hospital. Further studies with more representative samples are required. In addition, to examine the efficacy of statins, the baseline level of LDL-C should be considered, which was not performed in this study. Due to this limitation of our database, we are unable to show the reduction rate of the LDL-C level in order to evaluate the power of statins in detail. Furthermore, medication adherence was not examined. Further investigations are therefore required.
In conclusion, we surveyed the goal attainment rates for the LDL-C levels in type 2 diabetes mellitus patients. Our analysis of the lack of goal attainment in each prevention group provides useful suggestions for improving LDL-C management in patients with type 2 diabetes.
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